A Triple Delight: 3 Stocks All Up More Than 10%

It's not often you see good news for one company send its competitors up by double digits. But that's exactly what we're seeing in the obesity space today after the Food and Drug Administration released advisory committee documents for VIVUS' (Nasdaq: VVUS) obesity drug Qnexa.

Arena Pharmaceuticals (Nasdaq: ARNA) and Orexigen Therapeutics (Nasdaq: OREX) are benefiting from VIVUS' good fortunes because they also have advisory panel meetings scheduled before the end of the year. There was a lot of risk going into the meeting that the FDA might not approve any of the drugs.

There still is, in fact.

While there's nothing new in the documents to suggest the FDA will definitely reject Qnexa -- and that's the reason the stock is up more than 17% -- the risk still remains. Johnson & Johnson's (NYSE: JNJ) migraine and epilepsy drug Topomax makes up half of the active ingredients in Qnexa. The drug has some nasty side effects that were seen in some, albeit a small number, of the patients taking Qnexa. Heart complications in patients taking Qnexa were also cited by the FDA. In total, the agency is worried about five separate side-effect issues, including suicide and heart-related issues.

Predicting what the FDA will do is difficult because the risk-benefit analysis isn't simple. Obesity isn't an immediately life-threatening illness like cancer or even epilepsy, and there's already a relatively safe treatment: diet and exercise. Clearly there's still a need for a drug to help shed the pounds, but side effects can't be ignored, especially after Wyeth's fen-phen was pulled from the market. The FDA refused to approve sanofi-aventis' (NYSE: SNY) Acomplia, and Merck (NYSE: MRK) and Pfizer (NYSE: PFE) stopped development of their obesity drugs because of potential side-effect issues.

When the advisory committee meets Thursday, I think it's likely to recommend approval of Qnexa, and we'll see another jump in all three stocks. But remember, the FDA has the final say, and Arena's and Orexigen's drugs have separate risk-benefit issues of their own. Investors should be very cautious not to assume the companies have an easy layup from here.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a free 30-day trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is a Motley Fool Inside Value recommendation. Johnson & Johnson is an Income Investor recommendation, and Motley Fool Options recommended buying calls on the stock. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 13, 2010, at 7:45 PM, BioBat wrote:

    While the overall tone of the FDAs release was positive and there's nothing that says the FDA will reject Qnexa, the fact that the panel still isn't satisfied with the safety profile might signal a delay in approval. That's extremely welcome news to any ARNA and OREX holders.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1232255, ~/Articles/ArticleHandler.aspx, 10/23/2014 4:21:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement